Cardinal Health is re-rating from a low-margin drug distributor into a specialty-led clinical and home-care platform—if it can execute the MSO buildout and fix GMPD under tariffs.
Overview
Cardinal Health (CAH) is undergoing a major FY26-era re-architecture: from a high-volume, low-margin drug wholesaler into a diversified healthcare services platform with greater exposure to specialty medicines, provider enablement, and decentralized care delivery. Q3 FY26 results show the shift working financially—Pharmaceutical segment revenue rose to $56.1B (+11% YoY) and profit to $784M (+18%), helped by GLP-1 demand and richer specialty mix, while “Other” grew rapidly (revenue +31%, profit +34%) and delivered the company’s highest margins (~10.5%). The main operational weak spot remains Global Medical Products & Distribution (GMPD), where tariffs drove a steep profit decline despite stable revenue, making the medical turnaround central to a lasting valuation re-rating. Management has consistently beaten and raised guidance (FY26 non-GAAP EPS now $10.70–$10.80; adj. FCF $3.3B–$3.7B), supported by disciplined capital allocation (buybacks, dividends, and leverage within target). Key risks include MSO integration/value-based care complexity (highlighted by a $184M goodwill impairment), opioid settlement cash outflows, regulatory shifts (IRA/WAC, DSCSA, PBMs), biosimilar mix effects, and continued tariff uncertainty.